Ptc Therapeutics (PTCT) Income towards Parent Company (2012 - 2026)

Ptc Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 100.32% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 347.62% YoY), while the FY2025 annual figure was -$555.9 million, down 45.33% from the prior year.
• Income towards Parent Company was -$2.8 million for Q1 2026 at Ptc Therapeutics, up from -$1.4 billion in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $866.6 million in Q1 2025 to a low of -$1.4 billion in Q4 2025.
• Historically, Income towards Parent Company has averaged -$80.9 million across 5 years, with a median of -$106.7 million in 2024.
• Biggest YoY gain for Income towards Parent Company was 1046.28% in 2025; the steepest drop was 1513.47% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$204.6 million in 2022, then surged by 407.44% to $629.0 million in 2023, then plunged by 113.54% to -$85.1 million in 2024, then tumbled by 1513.47% to -$1.4 billion in 2025, then soared by 99.8% to -$2.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$2.8 million (Q1 2026), -$1.4 billion (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.